Poolbeg Pharma Investment Case

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from

Poolbeg Pharma, an infectious disease firm spun out from Irish vaccine research company Open Orphan, has been granted a patent by the US Patent and Trademark Office (USPTO). The US patent is related to methods introduced by Poolbeg

Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001. The US patent covers the use of POLB 001 and related p38 MAP kinase inhibitors

Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers

Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001. The treatment is a viral strain agnostic, small molecule immunomodulator which is

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

A Donegal man hopes to raise one billion dollars when his latest venture launches on New York’s Nasdaq. Poolbeg Pharma is planning to list on the stock exchange as chairman Cathal Friel (58), from Creeslough, eyes another $1bn

CAR-T therapies capitalize on the activities of T cells, the immune system’s natural hunters that prowl through the body looking for things that don’t belong. Foreign cells, or those infected with a virus, express unusual proteins that serve

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

Poolbeg Pharma, a biopharmaceutical company that specialises in infectious diseases, has filed a patent for one of its treatments to be used in cancer treatments. The treatment, called POLB 001, was developed to address severe influenza, but it